

股票代號 3164

景岳生物科技(股)公司

功能性益生菌領導品牌

GenMont Biotech Incorporation

The leading brand of functional probiotics

2023年法人說明會

葉天佑 協理

Alvin Yeh Senior Manager

2024年09月20日



全球益生菌市場快速發展

Global probiotics market is growing rapidly

全球市場分析報告顯示，**預計2026年全球益生菌市場約為911億美元**。



The global market analysis report shows that the global probiotic market is expected to be about 91.1 billion US dollars in 2026.

全球益生菌市場應用

Global probiotics market by product application

***市場分布 MARKET SHARE**

- 功能性食品 Functional food
- 保健食品與藥品 Health food and medicine
- 益生菌原料 Probiotics raw material



資料來源：

https://www.reportlinker.com/p05129364/Probiotics-Market-by-Application-Dietary-Supplements-Animal-Feed-Source-Form-End-User-And-Region-Forecast-to.html?utm_source=GNW;
<https://www.researchandmarkets.com/reports/5370159/global-probiotics-market-by-application>



2024年度研究成果介紹

The Annual Research Presentation 2024





186項研發專利

Patents over the world


▲各國專利申請張數

International patent applications by country




61篇文獻發表

Published Papers



人體臨床試驗列表

Human clinical trials



評估益生菌對於非酒精性脂肪肝病患者的效益以及腸道微生物所扮演的調節角色

摘要：

以早期非酒精性脂肪肝病患者食用6個月複合益生菌粉（熱滅活羅伊氏乳桿菌 GMNL-263+ 羅伊氏乳桿菌 GMNL-89+ 鼠李糖乳桿菌 GMNL-74）的臨床試驗結果，分析慢性發炎情形、全身性氧化壓力、碳水化合物和脂肪代謝，以及腸道微生態等指標，來評估益生菌對於非酒精性脂肪肝病的改善作用和預防惡化的機制。

試驗開始時間: 2022年7月14日

完成時間: 2024年3月

完成人數: 60人

試驗型態: 隨機分派的對照雙盲試驗

入案條件:

-20~80歲成年人/老人

-超音波診斷為非酒精性脂肪肝

-丙胺酸轉胺酶 (ALT, 肝功能指數)

檢測值為60-300 U/L



 National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov
RECRUITING ⓘ

To Evaluate the Beneficial Effect of Probiotics on NAFLD Patients and the Role of Gut Microbiota Modulation

ClinicalTrials.gov ID ⓘ NCT05402449

Sponsor ⓘ GenMont Biotech Incorporation

Information provided by ⓘ GenMont Biotech Incorporation (Responsible Party)

Last Update Posted ⓘ 2023-09-07

已完成臨床收案，
目前進行數據分析中

Brief Summary

In this study, the improvement of the clinical status of early-stage non-alcoholic fatty liver disease (NAFLD) patients after the probiotic intervention will be assessed. And the mechanism of probiotics to prevent the progression of illness would be investigated. The chronic inflammation status, systemic oxidative stress, metabolism of carbohydrates and lipid, and gut microbiota of NAFLD patients will also be analyzed.

Study Start (Actual) : 2022-07-14

Study Completion : 2024-03

Enrollment (Completed) : 60

Study Type :

Interventional (Randomized Controlled Trial)

Masking : Double (Participant, Investigator)

Dietary Supplement:

Probiotic group (Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 (alive))

Other: Placebo group

Eligibility Criteria

-Ages Eligible for Study: 20 Years to 80 Years (Adult, Older Adult)

-Inclusion Criteria:

- Diagnosis of Nonalcoholic fatty liver disease (NALFD) by ultrasound.
- The range of Alanine aminotransferase (ALT) blood test is 60-300 U/L

評估益生菌對於糖尿病腎病變患者的效益以及腸道微生物發揮的調節作用

摘要：

進行為期6個月的臨床試驗，讓糖尿病腎病變患者食用複合益生菌粉（羅伊氏乳桿菌 ADR-1+ 鼠李糖乳桿菌 GM-020），並監測血糖和腎功能相關指標。預期實驗結果，複合益生菌粉將經由抑制有害菌來改變腸道微生態，減少全身性氧化壓力和平衡碳水化合物與脂肪的代謝來改善糖尿病腎病變疾病，並進一步阻止糖尿病腎病變的惡化。

試驗開始時間: 2023年4月24日

完成時間: 2024年8月

完成人數: 44人

試驗型態: 隨機分派的對照雙盲試驗

入案條件:

- 25~80歲成年人/老人
- 患有第2型糖尿病並穩定服藥3個月
- 餐前 HbA1c 檢測在 7~10%
- 第1-3a 期糖尿病腎病變 (eGFR > 45 mL/min)
- 微量白蛋白尿達到 30~300 mg/day

NIH National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

RECRUITING ⓘ

To Evaluate the Beneficial Effect of Probiotics on DKD Patients and the Role of Gut Microbiota Modulation

ClinicalTrials.gov ID ⓘ NCT05674981

Sponsor ⓘ GenMont Biotech Incorporation

Information provided by ⓘ GenMont Biotech Incorporation (Responsible Party)

Last Update Posted ⓘ 2023-05-15

已完成臨床收案，
目前進行數據分析中

Brief Summary

To evaluate the efficacy of probiotics in the treatment of diabetic kidney disease, this study is designed to explore after consumption of probiotics lactobacillus reuteri ADR-1 and lactobacillus rhamnosus GM-020 composite strain powder sachets for 6 months, whether the improvement of blood sugar, kidney related indicators can further improve the course of diabetic kidney disease. The clinical trial predicted that probiotics can improve diabetic kidney disease by changing the intestinal flora by inhibiting harmful bacteria, reduction of systemic oxidative stress, balance carbohydrate and fat metabolism, further preventing the progress of diabetic kidney disease.

Study Start (Actual) : 2023-04-24

Study Completion : 2024-08

Enrollment (Completed) : 44

Study Type :

Interventional (Parallel Assignment, Randomized Controlled Trial)

Masking : Double (Participant, Investigator)

Eligibility Criteria

-Ages Eligible for Study: 25 Years to 80 Years (Adult, Older Adult)

-Inclusion Criteria:

- Suffering from type 2 diabetes and stable medication for 3 months
- Detection of HbA1c before meals between 7% and 10%
- Stage 1-3a diabetic nephropathies (eGFR > 45 mL/min)
- Microalbuminuria estimated between 30 to 300 mg/day

評估益生菌在乳癌患者的臨床效益

摘要：

化療相關的副作用會影響治療效果、生活質量，且對乳癌患者造成永久性傷害。因此透過本研究來探討在乳癌化療時，服用複合益生菌粉包6個月後，是否能減輕化療副作用，進而幫助患者順利完成療程。

試驗開始時間: 2024年4月8日

預計完成時間: 2026年4月1日

預計收案人數: 70人

試驗型態: 隨機分派的對照雙盲試驗

入案條件:

- 20~80歲成年人/老人
- 有接受anthracycline和taxane化學治療的1~3期乳癌患者 (不限於化學治療/手術前後)
- BMI > 18 kg/m²
- 經醫師評估且自願參加者



NIH National Library of Medicine
National Center for Biotechnology Information

ClinicalTrials.gov

RECRUITING ⓘ

To Evaluate the Clinical Efficacy of Probiotics in Patients With the Breast Cancer

ClinicalTrials.gov ID ⓘ NCT06039644

Sponsor ⓘ GenMont Biotech Incorporation

Information provided by ⓘ GenMont Biotech Incorporation (Responsible Party)

Last Update Posted ⓘ 2024-04-12

臨床受試者招募中

Brief Summary

Chemotherapy-associated side-effects would affect therapeutic effect, quality of life, and cause permanent harm to breast cancer patients. This study is designed to explore after consumption of probiotics of lactobacillus composite strain powder sachets for 6 months in breast cancer chemotherapy, and whether the improvement of meliorate the side effects, further assists patients completing the chemotherapy.

Study Start (Actual) : 2024-04-08

Study Completion (Estimated) : 2026-04-01

Enrollment (Estimated) : 70

Study Type :

Interventional (Parallel Assignment, Randomized Controlled Trial)

Masking : Double (Participant, Investigator)

Eligibility Criteria

-Ages Eligible for Study: 20 Years to 80 Years (Adult, Older Adult)

-Inclusion Criteria:

- Stage I-III breast patients using anthracycline-based and taxane-based chemotherapy (not limited before or after chemotherapy/surgery)
- BMI > 18 kg/m²
- Patients judged by physicians to participate in this trial and who are willing

乳酸桿菌功效研究

Efficacy studies of *Lactobacillus*

題目:奈米粒強化之後生元:以有效的載體運輸方式革新傳統癌症治療

Article: Nanoparticle-enhanced postbiotics: Revolutionizing cancer therapy through effective delivery. Life Sci. 2023 Dec 23:122379.

摘要:胃癌是導致癌症死亡的重大原因。其常用的化學治療方式因伴隨著嚴重的副作用而面臨挑戰，因而促使其他治療方式的開發研究，像是本篇所使用的後生元(從滅活益生菌衍生而來且更具安全性的生物分子)。儘管從體外試驗結果看來，後生元運用在癌症治療上是很有願景的，但在體內傳輸系統中是否能有效發揮作用仍是個挑戰。有鑑於此，本研究目標以奈米微粒結構來包埋 *Lacticaseibacillus paracasei* GMNL-133 (SGMNL-133)，探討奈米後生元在加強胃癌治療上的效果。透過優化GMNL-133裂解液的萃取和管柱沖提方法後，得到SGMNL-133，並開發奈米微粒來保護SGMNL-133免受胃酸影響，且能利用奈米微粒結構來加強黏膜穿透性，使更有效地將所裝載的功能性分子送到病灶處，提高跟胃癌細胞的相互作用，順利發揮抗癌治療效果。

Abstract: Gastric cancer contributes to cancer-related fatalities. Conventional chemotherapy faces challenges due to severe adverse effects, prompting recent research to focus on postbiotics, which are safer biomolecules derived from nonviable probiotics. Despite promising in vitro results, efficient in vivo delivery systems remain a challenge. This study aimed to design a potential nanoparticle (NP) formulation encapsulating the *Lacticaseibacillus paracasei* GMNL-133 (SGMNL-133) isolate to enhance its therapeutic efficacy in treating gastric cancer. Our study optimized the extraction of the lysate and column elution of GMNL-133, yielding SGMNL-133. We also developed NPs to protect SGMNL-133 from gastric acid, enhance mucus penetration, and improve the interaction with gastric cancer cells. This combination significantly enhanced drug delivery and anti-gastric tumor activity.



乳酸桿菌功效研究

Efficacy studies of *Lactobacillus*

題目: 乳酸桿菌透過增加蕈狀體神經細胞中的乳酸脫氫酶含量來改善果蠅記憶力

Article: Probiotic *Lactobacillus* spp. improves *Drosophila* memory by increasing lactate dehydrogenase levels in the brain mushroom body neurons.

Gut Microbes. 2024 Jan- Dec;16(1):2316533.

摘要: 益生菌是活的微生物，具有為宿主帶來健康效益的潛力，有時候還能影響行為反應。然而，益生菌影響宿主行為的詳細機制和潛在的生物效應仍不清楚。有鑒於此，透過在轉譯研究過程中，使用一種成熟的模式生物-黑腹果蠅和廣為人知的乳酸桿菌屬益生菌，來探討宿主與腸道微生物群之間的相互作用。實驗結果顯示，給予5天的GMNL-185和GMNL-680益生菌組合物在有顯著改善記憶功能的效果。其食用益生菌組合物的改善程度，藉由氣味訓練後的活體果蠅大腦蕈狀體神經細胞的鈣離子影像變化，可看到蕈狀體的β和γ蕈杯 (lobes) 的鈣離子影像反應增加。另外，在定量反轉錄聚合酶連鎖反應分析和全腦免疫組織化學染色結果看到，乳酸脫氫酶 (LDH) 表現量顯著增加。綜合上述結果證實，GMNL-185和GMNL-680益生菌組合物是經由增加腦中乳酸脫氫酶含量來加強果蠅的記憶功能。

Abstract: Probiotics are live microorganisms that offer potential benefits to their hosts and can occasionally influence behavioral responses. However, the detailed mechanisms by which probiotics affect the behavior of their hosts and the underlying biogenic effects remain unclear. Lactic acid bacteria, specifically *Lactobacillus* spp. are known probiotics. *Drosophila melanogaster*, commonly known as the fruit fly, is a well-established model organism for investigating the interaction between the host and gut microbiota in translational research. Herein, we showed that 5-day administration of a combined diet of *L. acidophilus* GMNL-185 and *L. rhamnosus* GMNL-680 demonstrated synergistic effects on memory functions. Live brain imaging revealed a significant increase in calcium responses to the training odor in the mushroom body β and γ lobes of flies that underwent mixed feeding with GMNL-185 and GMNL-680. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and whole-mount brain immunohistochemistry revealed significant upregulation of lactate dehydrogenase (LDH) expression in the fly brain following the mixed feeding. Notably, the genetic knockdown of LDH in neurons, specifically in mushroom body, ameliorated the beneficial effects of mixed feeding with GMNL-185 and GMNL-680 on memory improvement. Altogether, our results demonstrate that supplementation with *L. acidophilus* and *L. rhamnosus* enhances memory functions in flies by increasing brain LDH levels.

GUT MICROBES
2024 VOL. 16 NO. 1 2316533
https://doi.org/10.1080/19490976.2024.2316533



RESEARCH PAPER

OPEN ACCESS

Probiotic *Lactobacillus* spp. improves *Drosophila* memory by increasing lactate dehydrogenase levels in the brain mushroom body neurons

Shuk-Man Ho^a, Wan-Hua Tsai^{a,b}, Chih-Ho Lai^{a,c,d,e}, Meng-Hsuan Chiang^a, Wang-Po Lee^a, Hui-Yu Wu^a, Pei-Yi Bai^a, Tony Wu^a, and Chai-Lin Wu^{a,g}

^aDepartment of Biochemistry, Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, Department of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan; ^bResearch and Development Department, Genlink Biotech Incorporation, Tainan, Taiwan; ^cMolecular Infectious Disease Research Center, Department of Pediatrics, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan; ^dDepartment of Medical Research, School of Medicine, China Medical University and Hospital, Taichung, Taiwan; ^eDepartment of Nursing, Asia University, Taichung, Taiwan; ^fResearch Center for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan; ^gDepartment of Neurology, New Taipei Municipal Tucheng Hospital, Chang Gung Memorial Hospital, New Taipei City, Taiwan; ^hBrain Research Center, National Tsing Hua University, Hsinchu, Taiwan

ABSTRACT
Probiotics are live microorganisms that offer potential benefits to their hosts and can occasionally influence behavioral responses. However, the detailed mechanisms by which probiotics affect the behavior of their hosts and the underlying biogenic effects remain unclear. Lactic acid bacteria, specifically *Lactobacillus* spp. are known probiotics. *Drosophila melanogaster*, commonly known as the fruit fly, is a well-established model organism for investigating the interaction between the host and gut microbiota in translational research. Herein, we showed that 5-day administration of *Lactobacillus acidophilus* (formulated GMNL-185) or *Lactobacillus rhamnosus* (formulated GMNL-680) enhances olfactory-associative memory in *Drosophila*. Moreover, a combined diet of GMNL-185 and GMNL-680 demonstrated synergistic effects on memory functions. Live brain imaging revealed a significant increase in calcium responses to the training odor in the mushroom body β and γ lobes of flies that underwent mixed feeding with GMNL-185 and GMNL-680. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and whole-mount brain immunohistochemistry revealed significant upregulation of lactate dehydrogenase (LDH) expression in the fly brain following the mixed feeding. Notably, the genetic knockdown of LDH in neurons, specifically in mushroom body, ameliorated the beneficial effects of mixed feeding with GMNL-185 and GMNL-680 on memory improvement. Altogether, our results demonstrate that supplementation with *L. acidophilus* and *L. rhamnosus* enhances memory functions in flies by increasing brain LDH levels.

ARTICLE HISTORY
Received 21 September 2023
Revised 21 January 2024
Accepted 5 February 2024

KEYWORDS
Probiotics; *Lactobacillus*; Brain; Olfactory memory; Lactate dehydrogenase; *Drosophila melanogaster*

Introduction

A well-balanced gut microbiota is important for human health, and altering the composition of the gut microbiota could potentially impact the physiological responses of the host, leading to neural and behavioral changes.^{1–3} Gut microbiome is influenced by the dietary preferences and innate immune system of the host.^{4,5} Gut microbes can produce and utilize various neurotransmitters, including norepinephrine, dopamine, serotonin, and gamma-aminobutyric acid (GABA),^{6,7} which affect the physiological responses of the hosts.⁸ Accumulated evidence suggests that the gut microbiome is intricately involved in virtually all aspects

of nutrient metabolism within the host; however, the precise interactions between the gut microbiota and host physiology remain poorly understood.^{9,10} Probiotics are either single or combined live beneficial microorganisms, such as bacteria or yeast, that naturally inhabit the human body. Probiotic consumption is associated with several benefits, and it has been reported that probiotics could alleviate the symptoms of lactose intolerance, promote intestinal health, and reduce the risk of the development of various diseases.^{11–13}

Previous studies investigating the benefits of the gut microbiota on host health predominantly employed mammalian models. Numerous studies

CONTACT Chai-Lin Wu ^achlw@mail.cgu.edu.tw ^aDepartment of Biochemistry, Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan

^aSupplemental data for this article can be accessed online at <https://doi.org/10.1080/19490976.2024.2316533>

© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

乳酸桿菌功效研究

Efficacy studies of *Lactobacillus*

題目:經隨機雙盲、交叉設計具安慰劑對照組之試驗，探討副乾酪乳桿菌GMNL-143牙膏對於成人牙齦炎和口腔菌相的影響

Article: The impact of *Lactobacillus paracasei* GMNL-143 toothpaste on gingivitis and oral microbiota in adults: a randomized, double-blind, crossover, placebo-controlled trial.

BMC Oral Health. 2024 Apr 20; 24 (1):477.

摘要:本研究在探討熱滅活副乾酪乳桿菌GMNL-143對於口腔健康的益處，尤其在調節口腔菌相和改善牙齦炎的潛力上。透過隨機雙盲、交叉設計的臨床試驗，先使用4周的試驗牙膏 (GMNL-143或安慰劑) 後，進入1周的廓清期停止使用試驗牙膏，接著再交換使用4周的試驗牙膏，來評估GMNL-143牙膏對於牙齦炎症狀的改善程度。臨床試驗結果顯示，使用GMNL-143牙膏可降低牙齦炎指數，和減少牙齦溝液中的變異鏈球菌 (*S. mutans*) 含量。且從牙菌斑菌相中觀察到，牙齦指數與牙周致病菌含量呈正相關，而與彎曲菌屬呈負相關。綜合上述結果，GMNL-143牙膏可讓口腔菌相組成往較健康的口腔微生態發展，更證明了GMNL-143的確具有改善輕度到中度牙齦炎的潛力。

Abstract: This study examines the oral health benefits of heat-killed *Lactobacillus paracasei* GMNL-143, particularly its potential in oral microbiota alterations and gingivitis improvement. A randomized, double-blind, crossover clinical trial was performed on gingivitis patients using GMNL-143 toothpaste or placebo for four weeks, followed by a crossover after a washout. The results show that GMNL-143 toothpaste lowered the gingival index and reduced *Streptococcus mutans* in crevicular fluid. A positive relationship was found between *Aggregatibacter actinomycetemcomitans* and gingival index changes, and a negative one between *Campylobacter* and gingival index changes in plaque. In summary, GMNL-143 toothpaste may shift oral bacterial composition towards a healthier state, suggesting its potential in managing mild to moderate gingivitis.

Lee et al. BMC Oral Health (2024) 24:477
https://doi.org/10.1186/s12937-024-04231-4

BMC Oral Health

RESEARCH

Open Access

The impact of *Lactobacillus paracasei* GMNL-143 toothpaste on gingivitis and oral microbiota in adults: a randomized, double-blind, crossover, placebo-controlled trial

Min-Kang Lee¹, H-Hui Chen^{1*}, H-Jing Hsu², Wan-Hua Tsai³, Tzong-Yi Lee⁴, Jih-Hua Jhong⁵, Bai-Chia Liu², Tsai-Yin Huang⁶, Fang-Kuei Lin⁷, Wen-Wei Chang^{8,9} and Ju-Hui Wu^{1,2*}

Abstract

Background This study examines the oral health benefits of heat-killed *Lactobacillus paracasei* GMNL-143, particularly its potential in oral microbiota alterations and gingivitis improvement.

Methods We assessed GMNL-143's in vitro interactions with oral pathogens and its ability to prevent pathogen adherence to gingival cells. A randomized, double-blind, crossover clinical trial was performed on gingivitis patients using GMNL-143 toothpaste or placebo for four weeks, followed by a crossover after a washout.

Results GMNL-143 showed coaggregation with oral pathogens in vitro, linked to its surface layer protein. In patients, GMNL-143 toothpaste lowered the gingival index and reduced *Streptococcus mutans* in crevicular fluid. A positive relationship was found between *Aggregatibacter actinomycetemcomitans* and gingival index changes, and a negative one between *Campylobacter* and gingival index changes in plaque.

Conclusion GMNL-143 toothpaste may shift oral bacterial composition towards a healthier state, suggesting its potential in managing mild to moderate gingivitis.

Trial registration ID NCT04190485 (<https://clinicaltrials.gov/ct2/show/study?term=NCT04190485>), 09/12/2019, retrospective registration.

Keywords *Lactobacillus paracasei*, Gingivitis, Probiotic, toothpaste, Oral microbiota

*Tsai-Yin Huang and Wen-Hua Tsai contributed equally to this work.

*Correspondence:

Min-Kang Lee

changm@bmc.com

ju-hui.wu@bmc.com

¹Department of Dentistry, Kaohsiung Medical University Hospital, No.105,

Shih-Chuan 1st Road, Sanmin Dist., Kaohsiung City 807078, Taiwan

²Research and Development Department, GenMont Biotech

Incorporation, Taiwan City 741014, Taiwan

³Institute of Biomedical and Systems Biology, National Yang Ming

Chiao Tung University, Hsinchu 300035, Taiwan

⁴Department of Computer Science and Engineering, Nan Shu University,

Taichung City 400000, Taiwan

⁵Department of Biomedical Science, Chang Gung Medical University,

No. 105, Section 1, Chen Kuo Rd, Taichung City 402006, Taiwan

⁶Department of Medical Research, Chang Gung Medical University

Hospital, Taichung City 402006, Taiwan

⁷Department of Stomatology, College of Dental Medicine, Kaohsiung

Medical University, Kaohsiung City 807078, Taiwan



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



財務狀況 Financial status

※母公司財報-景岳生技 Separate Financial Statements-GenMont

單位：千元 In Thousands of New Taiwan Dollars	110母公司財報 (Year 2021 Single)	111年母公司財報 (Year 2022 Single)	112年母公司財報 (Year 2023 Single)
營業收入NET REVENUE	427,929	368,546	309,445
營業毛利GROSS PROFIT	299,326	258,019	211,231
營業費用OPERATING EXPENSES	(150,140)	(131,953)	(135,011)
營業利益INCOME(LOSS) FROM OPERATIONS	149,186	126,066	76,220
營業外損益NON- OPERATING INCOME AND EXPENSES	(6,231)	(50,291)	(37,497)
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	142,955	75,775	38,723
稅後淨利NET INCOME(LOSS)	113,132	56,978	32,991



財務狀況 Financial status

※合併財報 Consolidated Financial Statements

單位：千元 In Thousands of New Taiwan Dollars	111年合併 (Year 2022 Consolidated)	112年合併 (Year 2023 Consolidated)	113前二季合併 (Year 2024 H1 Consolidated)
營業收入NET REVENUE	368,546	318,015	210,603
營業毛利GROSS PROFIT	256,717	211,192	139,291
營業費用OPERATING EXPENSES	(194,747)	(204,204)	(98,903)
營業利益INCOME(LOSS) FROM OPERATIONS	61,970	6,988	40,388
營業外損益NON-OPERATING INCOME AND EXPENSES	4,288	21,175	17,736
稅前淨利INCOME(LOSS) BEFORE INCOME TAX	66,258	28,163	58,124
稅後淨利NET INCOME(LOSS)	47,461	22,431	44,890
停業單位損益Income (Loss)from Discountinued Operations	0	0	0
本期淨利NET INCOME(LOSS)	47,461	22,431	44,890



風險評估 Risk Assessment

生技領域方面財務風險Financial risk in the biotech sector

- 研發期間長 Long R & D period
 - 獲利回收晚 Late profit recovery
- ➡ 可能因此導致資金不足 Which may lead to insufficient funds

益生菌市場持續成長Probiotics market continues to grow

根據Precedence Research預估，2021年至2030年全球益生菌市場年平均複合成長率(CAGR)將可達8.7%，至2030年時其規模可達1,339億美元；其中食品飲料市場的規模最大(達75%以上)，動物飼料則成長最快速。目前市場以亞太地區為主，市場占比超過七成。

According to Precedence Research estimates, the global probiotics market will reach an average annual compound growth rate (CAGR) of 8.7% from 2021 to 2030, and its scale will reach US\$133.9 billion by 2030; the food and beverage market is the largest (up to 75% or more), animal feed is the fastest growing. At present, the market is dominated by the Asia-Pacific region, accounting for more than 70% of the market.





Thanks For Your Attention

Q & A

